<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02085655</url>
  </required_header>
  <id_info>
    <org_study_id>NKT-SYSUCC-2013</org_study_id>
    <nct_id>NCT02085655</nct_id>
  </id_info>
  <brief_title>PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma</brief_title>
  <official_title>PA-Gemox Regimen Followed by Thalidomide Versus AspaMetDex Regimen in NKTCL Patients：a Randomized, Open-label, Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huiqiang Huang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's
      lymphoma and shows extremely poor survival. This prospective pilot study to evaluate the
      efficacy and safety of long-acting aspargase (pegylated aspargase, PEG-ASP) combined with
      gemcitabine and oxaliplatin (PASP -Gemox) treatment in this population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility criteria The eligibility criteria were pathologically confirmed, previously
      untreated or refractory/relapsed ENKTL as defined by the World Health Organization
      classification; age≥18 years; Eastern Cooperative Oncology Group (ECOG) performance status of
      0-2; at least one measurable lesion; adequate haematologic function (haemoglobin &gt; 9.0 g/l,
      absolute neutrophil count &gt; 1500/ml, platelets &gt; 75,000/l), hepatic function (total serum
      bilirubin ≤ 1.5 times the upper limit of normal, alanine aminotransferase and aspartate
      aminotransferase ≤ 2.5 times the upper limit of normal), renal function (serum creatinine ≤
      1.5 mg/dl, creatinine clearance ≥ 50 ml/min); normal coagulation function and
      electrocardiogram results. Prior chemotherapy and radiotherapy should have been completed &gt;4
      weeks earlier, willingness to provide written informed consent. Stage was defined according
      to the Ann Arbor system. The Sun Yat-Sen University Cancer Centre Research Ethics Board
      approved this study before subjects were enrolled.

      Treatment PA-Gemox dosages were as follows: days 1 and 8, 30-min intravenous infusion of 1000
      mg/m2 gemcitabine; day 1, 2-h intravenous infusion of 130 mg/m2 oxaliplatin; day 1, deep
      intramuscular injection of 2500 U/m2 PEG-ASP at two different sites. The regimen was repeated
      every 3 weeks for a maximum of six cycles. Stage IE/IIE patients underwent four cycles
      induction chemotherapy, followed by involved-field radiotherapy after got CR, PR or SD.
      Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per
      daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
      Refractory/relapsed patients underwent at least two cycles treatments unless there was
      disease progression or unacceptable side effects, or withdrawal of patient consent.
      Autologous haematopoietic stem cell transplantation (AHSCT) was recommended after they
      achieved CR.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Outcome Measure</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Study group increase 15% 2-year PFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety/Adverse Event Outcome Measure</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Number of Participants with Serious and Non-Serious Adverse Events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy Outcome Measure</measure>
    <time_frame>Up to 36 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type</condition>
  <arm_group>
    <arm_group_label>PEG-ASP+Gemox regimen group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-ASP 2000U/m2 im d1 Gemcitabine 800mg/m2 ivdrip 30min d1，8 Oxaliplatin 100mg/m2 ivdrip d1 Thalidomide 150-200mg po qn d8-21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AspaMetDex regimen group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegaspargase 2000U/m2 im， d1 methotrexate 3000m g/m2 civ 6-hour，d1, Calcium folinate 30mg iv q6h x6 Dexamethasone 40 mg ivdrip QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
    <description>pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>PEG-ASP+Gemox regimen group</arm_group_label>
    <arm_group_label>AspaMetDex regimen group</arm_group_label>
    <other_name>Oncaspar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000mg/m2, ivd on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>PEG-ASP+Gemox regimen group</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>100mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops</description>
    <arm_group_label>PEG-ASP+Gemox regimen group</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>AspaMetDex regimen group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40mg ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>AspaMetDex regimen group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>100-200mg, PO, after chemotherapy</description>
    <arm_group_label>PEG-ASP+Gemox regimen group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. pathologically confirmed, previously untreated or refractory/relapsed ENKTL as defined
             by the World Health Organization classification;

          2. age≥18 years;

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

          4. at least one measurable lesion;

          5. adequate haematologic function (haemoglobin &gt; 9.0 g/l, absolute neutrophil count &gt;
             1500/ml, platelets &gt; 75,000/l),

          6. adequate hepatic function (total serum bilirubin ≤ 1.5 times the upper limit of
             normal, alanine aminotransferase and aspartate aminotransferase ≤ 2.5 times the upper
             limit of normal),

          7. adequate renal function (serum creatinine ≤ 1.5 mg/dl, creatinine clearance ≥ 50
             ml/min);

          8. normal coagulation function and electrocardiogram results.

          9. Prior chemotherapy and radiotherapy should have been completed &gt;4 weeks earlier,

         10. willingness to provide written informed consent.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HuiQiang Huang</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HuiQiang Huang</last_name>
    <phone>86-020-87343350</phone>
    <email>huanghq@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medical Oncology, Sun Yat-sen University Cancer Center,</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HuiQiang Huang</last_name>
      <phone>86-020-87343350</phone>
      <email>huanghq@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2014</study_first_submitted>
  <study_first_submitted_qc>March 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <last_update_submitted>March 12, 2014</last_update_submitted>
  <last_update_submitted_qc>March 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Huiqiang Huang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Extranodal NK/T-cell lymphoma</keyword>
  <keyword>PA-Gemox regimen</keyword>
  <keyword>thalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

